Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis
For multiple myeloma patients who've already tried one CAR-T therapy, switching to a different target appears significantly more effective than repeating the same approach.
This systematic review and meta-analysis of 34 studies (n=1280) establishes that GPRC5D-directed CAR-T significantly outperforms BCMA-directed CAR-T (77% vs 52% ORR vs engineered antibodies) in patients who relapsed after prior BCMA-targeted therapy. Key actionable findings include GPRC5D antigen superiority and the importance of allowing ≥10 months before retreatment, directly informing sequencing decisions in the post-BCMA R/R MM landscape.
What the study was
- Study design
- systematic_review_meta_analysis
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Blood Cancer Journal
Why it surfaced
Highest-impact hematology/immunotherapy article of this window: first large SR+MA establishing evidence-based treatment sequencing in post-BCMA R/R MM with directly actionable antigen selection guidance. Score 9 reflects SR+MA design (D=2), high unmet need (P=2), and immediate clinical applicability (E=2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.